Analysis of efficacy and safety of low-dose roxadustat in the treatment of uremic patients with anemia after arteriovenous fistula surgery
Objective To observe the efficacy and safety of low-dose roxadustat in the treatment of uremic patients with anemia after arteriovenous fistula surgery.Methods 48 cases of uremic patients with anemia after arteriovenous fistula surgery were studied and randomly divided into a treatment group(23 cases)and a control group(25 cases).The treatment group was treated with low-dose roxadustat,while the control group was treated with erythropoietin(EPO).Patients in both groups were compared in terms of hemoglobin,blood pressure(systolic blood pressure and diastolic blood pressure),serum iron,serum ferritin(SF),transferrin saturation(TSAT),C-reactive protein(CRP),intact parathyroid hormone(iPTH)and electrolyte(potassium ions,sodium ions,chloride ions,calcium ions,phosphate)changes at different follow-up stages(baseline,3 months,6 months,9 months and 12 months after surgery),and occurrence of adverse reactions.Results There was no statistically significant difference between the two groups when comparing the baseline hemoglobin,postoperative mean hemoglobin,baseline compliance rate,and postoperative mean compliance rate(P>0.05).In the treatment group,the hemoglobin of(105.87±19.48)g/L at 12 months after surgery was higher than(94.70±16.49)g/L at baseline,and there was a significant difference(t=2.099,P=0.042<0.05);there was no statistically significant difference in the comparison of hemoglobin at 3,6,and 9 months after surgery compared with that at baseline(P>0.05).In the control group,there was no statistically significant difference in hemoglobin at baseline compared with 3,6,9,and 12 months after surgery(P>0.05).There was no statistically significant difference in the comparison of hemoglobin at 3,6,9,and 12 months after surgery between the two groups(P>0.05).There was no statistical difference between the two groups in comparison of systolic blood pressure and diastolic blood pressure at baseline,3 months after surgery,6 months after surgery,9 months after surgery,and 12 months after surgery(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).There was no significant difference in serum iron between the two groups at baseline,3 months,6 months,9 months and 12 months after surgery(P>0.05).There were no significant differences in SF and TSAT between the two groups at baseline,3 months,6 months and 9 months after surgery(P>0.05).At 12 months after surgery,the treatment group had SF of(255.83±80.79)μg/L and TSAT of(27.59±7.35)%,which were higher than(207.96±66.02)μg/L and(23.59±6.13)%in the control group,and there were significant differences(P<0.05).There was no significant difference in CRP,iPTH,potassium ion,sodium ion,chloride ion,calcium ion and phosphate between the two groups at baseline,3 months after surgery,6 months after surgery,9 months after surgery and 12 months after surgery(P>0.05).Conclusion The effect of low-dose roxadustat on uremic patients with anemia after arteriovenous fistula surgery is better than EPO,and it has high safety.
NETL
NSTL
万方数据
